Omeros’ (OMER) “Buy” Rating Reaffirmed at D. Boral Capital

Omeros (NASDAQ:OMER)‘s stock had its “buy” rating reiterated by analysts at D. Boral Capital in a report released on Friday,Benzinga reports. They presently have a $36.00 target price on the biopharmaceutical company’s stock. D. Boral Capital’s price target indicates a potential upside of 357.43% from the stock’s current price.

Several other research firms have also recently weighed in on OMER. WBB Securities reaffirmed a “strong-buy” rating and set a $45.00 price objective on shares of Omeros in a research report on Wednesday, October 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Omeros in a research report on Wednesday, October 8th. HC Wainwright raised their price target on shares of Omeros from $9.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, October 15th. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a report on Wednesday, October 15th. Finally, Wall Street Zen upgraded shares of Omeros from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $33.67.

Omeros Price Performance

OMER traded up $1.59 during trading on Friday, reaching $7.87. The company had a trading volume of 4,806,214 shares, compared to its average volume of 1,622,912. The business’s fifty day moving average price is $5.71 and its 200 day moving average price is $4.59. Omeros has a 12 month low of $2.95 and a 12 month high of $13.60. The company has a market cap of $535.60 million, a P/E ratio of -3.73 and a beta of 2.40.

Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Thursday, November 13th. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.39. As a group, sell-side analysts predict that Omeros will post -3.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Omeros

Hedge funds have recently bought and sold shares of the company. Deutsche Bank AG raised its stake in Omeros by 4.9% in the first quarter. Deutsche Bank AG now owns 42,019 shares of the biopharmaceutical company’s stock valued at $345,000 after buying an additional 1,973 shares during the period. Wealth Enhancement Advisory Services LLC raised its stake in Omeros by 11.2% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 29,097 shares of the biopharmaceutical company’s stock valued at $129,000 after acquiring an additional 2,941 shares during the period. Harbour Investments Inc. lifted its holdings in Omeros by 51.9% during the 1st quarter. Harbour Investments Inc. now owns 9,218 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 3,149 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Omeros by 2.2% during the first quarter. Bank of New York Mellon Corp now owns 151,062 shares of the biopharmaceutical company’s stock worth $1,242,000 after purchasing an additional 3,321 shares during the period. Finally, Russell Investments Group Ltd. increased its holdings in shares of Omeros by 113.1% in the third quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 5,677 shares during the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.